Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics:
- Introduction: Clinical Trials We LOVE to Discuss (0:00)
- Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42)
- Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory Multiple Myeloma (MM) (15:59)
- Extramedullary Disease (19:23)
- Spectrum and Management of CELMoD-Associated Adverse Events (30:12)
- Ongoing Phase II and III Trials Evaluating CELMoDs for MM (34:53)